Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.54 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.50 |
| ▸ | KCNJ1 | P48048 | 3/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7345284 | 0.84 | KCNJ1 (0.59) | ALDH1A1KCNJ1HTTKMT2AMEN1 | |
| SCHEMBL3171647 | 0.83 | KCNJ1 (0.58) | ALDH1A1KCNJ1HTTKMT2AMEN1 | |
| SCHEMBL18788160 | 0.82 | HRH3 (0.56) | ALDH1A1HRH3SIGMAR1LMNACYP2D6 | |
| SCHEMBL1928086 | 0.82 | HRH3 (0.56) | ALDH1A1HRH3LMNACYP2D6SMN1; SMN2 | |
| SCHEMBL21412829 | 0.82 | CA12 (0.56) | ALDH1A1HRH3KCNJ1SIGMAR1HTT | |
| SCHEMBL31378757 | 0.81 | HRH3 (0.55) | ALDH1A1HRH3LMNACYP2D6SMN1; SMN2 | |
| SCHEMBL5381731 | 0.79 | KMT2A (0.54) | ALDH1A1KCNJ1HTTKMT2AMEN1 | |
| SCHEMBL1929880 | 0.79 | LTA4H (0.57) | ALDH1A1HRH3KMT2AMEN1LMNA | |
| SCHEMBL264564 | 0.79 | LTA4H (0.57) | ALDH1A1HRH3KMT2AMEN1LMNA | |
| SCHEMBL2076533 | 0.78 | MAPT (0.53) | ALDH1A1HRH3SIGMAR1KCNH2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7220777-B2 | Lactam derivatives as antagonists for human 11cby receptors | SMITHKLINE BEECHAM P.L.C. (GB) | 2007-05-22 | — | — | US | disclosed |
| EP-1436267-B1 | LACTAM DERIVATIVES AS ANTAGONISTS FOR HUMAN 11CBY RECEPTORS | SMITHKLINE BEECHAM PLC (GB) | 2006-12-27 | — | — | EP | disclosed |
| US-20060287321-A1 | Novel Lactam Derivatives | SMITHKLINE BEECHAM P.L.C. (GB) | 2006-12-21 | — | — | US | disclosed |
| US-20050059651-A1 | Lactam derivatives as antagonists for human 11cby receptors | SMITHKLINE BEECHAM P.L.C. (GB) | 2005-03-17 | — | — | US | disclosed |
| EP-1436267-A1 | LACTAM DERIVATIVES AS ANTAGONISTS FOR HUMAN 11CBY RECEPTORS | SMITHKLINE BEECHAM PLC (GB) | 2004-07-14 | — | — | EP | disclosed |
| WO-2003033480-A1 | LACTAM DERIVATIVES AS ANTAGONISTS FOR HUMAN 11CBY RECEPTORS | SMITHKLINE BEECHAM PLC (GB) | 2003-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050059651-A1 | Lactam derivatives as antagonists for human 11cby receptors | ADRB3, GPR3, ADRB1 | ALDH1A1 2468/4885HRH3 714/4885KCNJ1 2230/4885 |
| US-20060287321-A1 | Novel Lactam Derivatives | MRPL21, PEPD, STS | ALDH1A1 2328/4885HRH3 3756/4885KCNJ1 3489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.